Suchergebnisse - "Gossec, Laure"

PubPharm (32)

1

Guselkumab provides durable improvement across psoriatic arthritis disease domains : post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

enthalten in: RMD open | 2024

von Coates, L. | Gossec, L. | Zimmermann, M. | +8

2

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis : 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study

enthalten in: Annals of the rheumatic diseases | 2023

von Ritchlin, C. | Coates, L. | McInnes, I. | +12

3

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

enthalten in: Rheumatology (Oxford, England) | 2023

von Coates, L. | Ritchlin, C. | Gossec, L. | +12

4

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years : results from BE ACTIVE

enthalten in: Rheumatology (Oxford, England) | 2023

von Mease, P. | Asahina, A. | Gladman, D. | +8

CommentIn: Nat Rev Rheumatol. 2022 Sep;18(9):494. - PMID 35922551

5

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment : a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

enthalten in: Lancet (London, England) | 2023

von McInnes, I. | Asahina, A. | Coates, L. | +13

CommentIn: Lancet. 2023 Jan 7;401(10370):2-3. - PMID 36495880

6

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors : a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

enthalten in: Lancet (London, England) | 2023

von Merola, J. | Landewé, R. | McInnes, I. | +16

7

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis : Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2022

von Coates, L. | McInnes, I. | Merola, J. | +9

CommentIn: Nat Rev Rheumatol. 2022 Sep;18(9):494. - PMID 35922551

8

Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis : Long-Term Results of Two Phase III Randomized Controlled Trials

enthalten in: Arthritis care & research | 2022

von Kvien, T. | Conaghan, P. | Gossec, L. | +8

9

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors : results through one year of a phase IIIb, randomised, controlled study (COSMOS)

enthalten in: Annals of the rheumatic diseases | 2022

von Coates, L. | Gossec, L. | Theander, E. | +7

10

Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics : a multicentre randomised clinical trial

enthalten in: RMD open | 2022

von Beauvais, C. | Fayet, F. | Rousseau, A. | +16